The recent phase III ORIENT-11 trial showed that in patients with EGFR and ALK mutation-negative advanced or metastatic nonsquamous NSCLC, the addition of sintilimab to standard chemotherapy with pemetrexed and platinum, significantly prolonged PFS compared (8.9 mo versus 5.0 mo, HR, 0.482, p < 0.00001) [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.